Literature DB >> 29471391

Comparative efficacy of enrofloxacin to that of tulathromycin for the control of bovine respiratory disease and prevalence of antimicrobial resistance in Mannheimia haemolytica in calves at high risk of developing bovine respiratory disease.

S Crosby1, B Credille1, S Giguère2, R Berghaus1.   

Abstract

Bovine respiratory disease (BRD) is the most common cause of morbidity and mortality in North American beef cattle. Mannheimia haemolytica is the bacterial pathogen most often isolated from cattle with BRD, and the prevalence of antimicrobial resistance (AMR) in this organism has increased in recent years. Antimicrobials are commonly used to prevent BRD in cattle at high risk of developing BRD; however, recent work would suggest that this practice might be one factor contributing to the increased prevalence of AMR in M. haemolytica. We hypothesized that the administration of the short-acting fluoroquinolone, enrofloxacin, would be just as effective as the long-acting triamilide, tulathromycin, in preventing BRD but would be less likely to select for AMR M. haemolytica in stocker calves at high risk of developing BRD. Three hundred forty-one stocker calves were enrolled in the study with 172 calves in 4 pens being randomly assigned to treatment with enrofloxacin and 169 calves in 4 pens randomly assigned to treatment with tulathromycin. Calves within each treatment group were allocated to one of 4 replicate pens based on the week of enrollment. Of calves receiving enrofloxacin, 33.7% required treatment for BRD at least once within 45 d after arrival, compared with 18.3% of calves receiving tulathromycin (P = 0.040). The percentages of calves that required more than one treatment for BRD within 45 d after arrival did not differ statistically for those receiving enrofloxacin compared with those receiving tulathromycin (10.5% and 4.7%, respectively; P = 0.107) Likewise, the percentages of calves that died during the 45-d follow-up period did not differ for those receiving enrofloxacin compared with those receiving tulathromycin (12.2% and 10.1%, respectively; P = 0.592). Mannheimia haemolytica was cultured from 11% of calves sampled at arrival and from 50% of calves sampled at revaccination 14 to 17 d later. There was a significanst effect of sampling time on the proportion of calves carrying multidrug-resistant (MDR) isolates, with calves having a higher prevalence of MDR isolates at revaccination than arrival (100% vs. 13%; P < 0.001). Future research evaluating the impact of MDR on response to antimicrobial therapy is necessary.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29471391      PMCID: PMC6140942          DOI: 10.1093/jas/sky054

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  25 in total

Review 1.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

3.  Comparison of tulathromycin and tilmicosin on the prevalence and severity of bovine respiratory disease in feedlot cattle in association with feedlot performance, carcass characteristics, and economic factors.

Authors:  T C Tennant; S E Ives; L B Harper; D G Renter; T E Lawrence
Journal:  J Anim Sci       Date:  2014-11       Impact factor: 3.159

4.  Efficacy of tulathromycin in the treatment and prevention of natural outbreaks of bovine respiratory disease in European cattle.

Authors:  Kevin S Godinho; Regina M-L G Wolf; John Sherington; Tim G Rowan; Simon J Sunderland; Nigel A Evans
Journal:  Vet Ther       Date:  2005

5.  Disposition of gamithromycin in plasma, pulmonary epithelial lining fluid, bronchoalveolar cells, and lung tissue in cattle.

Authors:  Steeve Giguère; Rose Huang; Thomas J Malinski; Paul M Dorr; Ronald K Tessman; Bruce A Somerville
Journal:  Am J Vet Res       Date:  2011-03       Impact factor: 1.156

Review 6.  Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle.

Authors:  Jason S Nickell; Brad J White
Journal:  Vet Clin North Am Food Anim Pract       Date:  2010-07       Impact factor: 3.357

7.  Effects of on-arrival versus delayed clostridial or modified live respiratory vaccinations on health, performance, bovine viral diarrhea virus type I titers, and stress and immune measures of newly received beef calves.

Authors:  J T Richeson; E B Kegley; M S Gadberry; P A Beck; J G Powell; C A Jones
Journal:  J Anim Sci       Date:  2009-03-13       Impact factor: 3.159

8.  Mannheimia haemolytica in feedlot cattle: prevalence of recovery and associations with antimicrobial use, resistance, and health outcomes.

Authors:  N R Noyes; K M Benedict; S P Gow; C W Booker; S J Hannon; T A McAllister; P S Morley
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

9.  Comparison of Active Drug Concentrations in the Pulmonary Epithelial Lining Fluid and Interstitial Fluid of Calves Injected with Enrofloxacin, Florfenicol, Ceftiofur, or Tulathromycin.

Authors:  Derek M Foster; Luke G Martin; Mark G Papich
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 10.  Board-invited review: recent advances in management of highly stressed, newly received feedlot cattle.

Authors:  G C Duff; M L Galyean
Journal:  J Anim Sci       Date:  2006-11-03       Impact factor: 3.159

View more
  7 in total

1.  Characterization and comparison of cell-mediated immune responses following ex vivo stimulation with viral and bacterial respiratory pathogens in stressed and unstressed beef calves1.

Authors:  Veronica M Buhler; Kaycee R Cash; David J Hurley; Brent C Credille
Journal:  J Anim Sci       Date:  2019-07-02       Impact factor: 3.159

2.  Pathogenic Mannheimia haemolytica Invades Differentiated Bovine Airway Epithelial Cells.

Authors:  Daniel Cozens; Erin Sutherland; Miquel Lauder; Geraldine Taylor; Catherine C Berry; Robert L Davies
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  In-vitro antibiotic resistance phenotypes of respiratory and enteric bacterial isolates from weaned dairy heifers in California.

Authors:  Sarah Depenbrock; Sharif Aly; John Wenz; Deniece Williams; Wagdy ElAshmawy; Kristin Clothier; Heather Fritz; Gary McArthur; Meera Heller; Munashe Chigerwe
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

Review 4.  Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Authors:  Łukasz Grabowski; Lidia Gaffke; Karolina Pierzynowska; Zuzanna Cyske; Marta Choszcz; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

5.  Antimicrobial Resistance in Members of the Bacterial Bovine Respiratory Disease Complex Isolated from Lung Tissue of Cattle Mortalities Managed with or without the Use of Antimicrobials.

Authors:  Kim Stanford; Rahat Zaheer; Cassidy Klima; Tim McAllister; Delores Peters; Yan D Niu; Brenda Ralston
Journal:  Microorganisms       Date:  2020-02-20

6.  Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples.

Authors:  Johann F Coetzee; Drew R Magstadt; Pritam K Sidhu; Lendie Follett; Adlai M Schuler; Adam C Krull; Vickie L Cooper; Terry J Engelken; Michael D Kleinhenz; Annette M O'Connor
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

7.  Concordance of disk diffusion, broth microdilution, and whole-genome sequencing for determination of in vitro antimicrobial susceptibility of Mannheimia haemolytica.

Authors:  Emily R Snyder; Bridget J Savitske; Brent C Credille
Journal:  J Vet Intern Med       Date:  2020-09-07       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.